Evidence map›Paper›PMID 39345136›Full record

ArticlemBio2024

SARS-CoV-2 ORF3a induces COVID-19-associated kidney injury through HMGB1-mediated cytokine production.

Chenyu Zhang, Volodymyr Gerzanich, Ruth Cruz-Cosme, Jiantao Zhang, Orest Tsymbalyuk, Cigdem Tosun, Bhargava Teja Sallapalli, Dongxiao Liu, Kaspar Keledjian, John C Papadimitriou and 6 more

Abstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chenyu ZhangDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Volodymyr GerzanichDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Ruth Cruz-CosmeDepartment of Microbiology, Howard University College of Medicine, Washington, DC, USA.
Jiantao ZhangDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Orest TsymbalyukDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Cigdem TosunDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Bhargava Teja SallapalliDepartment of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.
Dongxiao LiuDepartment of Microbiology, Howard University College of Medicine, Washington, DC, USA.ORCID 0000-0001-9656-8976
Kaspar KeledjianDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
John C PapadimitriouDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Cinthia B DrachenbergDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Mohamed NasrDivision of AIDS, NIAID, NIH, Drug Development and Clinical Sciences Branch, Bethesda, Maryland, USA.
Yanjin ZhangDepartment of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.ORCID 0000-0002-5847-3260
Qiyi TangDepartment of Microbiology, Howard University College of Medicine, Washington, DC, USA.ORCID 0000-0002-6487-2356
J Marc SimardDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-5373-1988
Richard Y ZhaoDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-3424-2852

Funding

Sleep Disorders in Adults with Sickle Cell Disease: Frequency, Associations with Cardiovascular and Pain Indicators, and Responses to TreatmentU54MD007597 · NIMHD · HOWARD UNIVERSITY · PI Tatiana V.D. Sanses · 2019 to 2026
$37.7M
PROTEOMICS CORE FACILITYG12MD007597 · NIMHD · HOWARD UNIVERSITY · PI SOUTHERLAND, WILLIAM M. · 2012 to 2018
$14.8M
Sulfonylurea receptor 1 (SUR1)- A novel therapeutic target in ischemic strokeR01HL082517 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SIMARD, J. MARC · 2006 to 2021
$5.6M
Molecular Neuro-pathogenesis of Congenital Cytomegalovirus InfectionSC1AI112785 · NIAID · PONCE SCHOOL OF MEDICINE · PI TANG, QIYI · 2014 to 2021
$2.8M
Fn14, non-canonical NF-kappaB and downstream signaling in neuropathic painR01NS105633 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI SIMARD, J. MARC · 2018 to 2022
$1.9M
Non-canonical NF-kappaB signaling and Sur1-Trpm4 in traumatic brain injuryR01NS102589 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI SIMARD, J. MARC · 2017 to 2021
$1.7M
Sur1-Trpm4 regulation of the pro-inflammatory astrocytic secretome in EAER01NS107262 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI GERZANICH, VLADIMIR · 2020 to 2024
$1.7M
A Novel Cell-based System for the Search of SARS-CoV-2 ORF3a Inhibitors against COVID-19R21AI175931 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI ZHAO, RICHARD YUQI · 2024 to 2025
$428k
Viral Protein R (Vpr) in HIV-associated Brain Neuroinflammation and NeurotoxicityI01BX004652 · VA · BALTIMORE VA MEDICAL CENTER · PI J. Marc Simard, RICHARD YUQI ZHAO · 2020 to 2026
–
Therapeutic potential and the critical site of action of non-addicting glibenclamide in neuropathic painI01RX003060 · VA · BALTIMORE VA MEDICAL CENTER · PI SIMARD, J. MARC · 2020 to 2023
–
BLRD VA I01 BX004652HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL082517HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R21AI175931HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) SC1AI112785HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS102589, R01NS105633HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS107262HHS | NIH | National Institute on Minority Health and Health Disparities (NIMHD) G12MD007597NHLBI NIH HHS R01 HL082517NIAID NIH HHS R21 AI175931NIAID NIH HHS SC1 AI112785NIMHD NIH HHS G12 MD007597NIMHD NIH HHS U54 MD007597NINDS NIH HHS R01 NS102589NINDS NIH HHS R01 NS105633NINDS NIH HHS R01 NS107262RRD VA I01 RX003060U.S. Department of Defense (DOD) SC170199U.S. Department of Veterans Affairs (VA) I01BX004652U.S. Department of Veterans Affairs (VA) I01RX003060 ,I01BX004652
6 · The paper itself

Abstract

The primary challenge posed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is COVID-19-related mortality, often exacerbated by additional medical complications, such as COVID-19-associated kidney injuries (CAKIs). Up to half of COVID-19 patients experience kidney complications, with those facing acute respiratory failure and kidney injury having the worst overall prognosis. Despite the significant impact of CAKI on COVID-19-related mortality and its enduring effects in long COVID, the underlying causes and molecular mechanisms of CAKI remain elusive. In this study, we identified a functional relationship between the expression of the SARS-CoV-2 ORF3a protein and inflammation-driven apoptotic death of renal tubular epithelial cells in patients with CAKI. We demonstrate IMPORTANCE: The major challenge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the pandemic is COVID-19-related mortality, which has tragically claimed millions of lives. COVID-19-associated morbidity and mortality are often exacerbated by pre-existing medical conditions, such as chronic kidney diseases (CKDs), or the development of acute kidney injury (AKI) due to COVID-19, collectively known as COVID-19-associated kidney injuries (CAKIs). Patients who experience acute respiratory failure with CAKI have the poorest clinical outcomes, including increased mortality. Despite these alarming clinical findings, there is a critical gap in our understanding of the underlying causes of CAKI. Our study establishes a direct correlation between the expression of the SARS-CoV-2 viral ORF3a protein and kidney injury induced by ORF3a linking to CAKI. This functional relationship was initially observed in our clinical studies of COVID-19 patients with AKI and was further validated through animal and

Indexed as

COVID-19CytokinesHMGB1 ProteinSARS-CoV-2Viroporin ProteinsAcute Kidney InjuryAnimalsApoptosisEpithelial CellsHumansKidneyMaleMiceMice, Inbred C57BLCytokinesHMGB1 ProteinHMGB1 protein, humanORF3a protein, SARS-CoV-2Viroporin ProteinsCAKIglycyrrhizinHMGB1K18-hACE2 miceNF-kBORF3aSARS-CoV-2TNFα and IL-6viral infection

Identifiers

PMID39345136
PMCPMC11559048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.